SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Anxiety, Separation Clinical Trial

Official title:
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).

Status Completed

Clinical Trial Summary

This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01470469
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 2
Start date	January 4, 2012
Completion date	July 15, 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02310152` - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)	N/A
Completed	`NCT00012584` - Treatment of Youth With ADHD and Anxiety	N/A
Recruiting	`NCT02459509` - A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children	Phase 4
Completed	`NCT04950088` - Reduction of Perioperative Anxiety Using a Hand-held Video Game Device	N/A
Recruiting	`NCT04598230` - Partners in Caring for Anxious Youth	Phase 3
Completed	`NCT02027844` - Cartoon Distraction and Parental Presence on Anxiety in Pediatric Anesthesia	N/A
Completed	`NCT04414501` - Comparison of Virtual Reality to Tablet-based Distraction in Children	N/A